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reabsorptive capacity vanes with short-term changes in Pi sup-
ply. We also studied if it varies with a short-term variation of a Pi
requirement, which can be expected to occur during fasting. Us-
ing clearance methodology we studied the influence of overnight
fasting on the tubular capacity to reabsorb Pi in rats. Fasted ani-
mals were or were not supplemented with Pi in amounts corre-
sponding to those absorbed by the fed group. This protocol al-
lowed us to dissociate the effect of overnight fasting per se from
that of overnight Pi deprivation. Tubular Pi reabsorptive capac-
ity was found to be lower in overnight fasted animals receiving a
Pi supplement in the drinking water than in fed animals. In over-
night fasting rats it was lower in animals receiving a Pi supple-
ment in the drinking water than in those without Pi supplement.
There was no difference in tubular Pi reabsorptive capacity be-
tween completely fasted and fed rats. These results indicate that
overnight fasting with constant Pi supply decreases the tubular
reabsorptive capacity for Pi, whereas overnight Pi deprivation
stimulates it. These two opposite effects explain the fact that
overnight fasting without Pi supplement has no significant influ-
ence on tubular Pi transport capacity. Furthermore, these results
show that the kidney can adapt its transport capacity for Pi ac-
cording to short-term changes in Pi supply and requirement, that
is in less than 14 hours.
Double-blind comparison of three antihypertensive drugs by in.
ternists in private practice. B. Waeber, H. R. Brunner, R. K. Fer-
guson, G. A. Turini, H. Gavras. Centre Hospital ier Universitaire
Vaudois, Lausanne, Switzerland. The antihypertensive effects of
debrisoquine, methyldopa, and propranolol were studied in a
double-blind fashion by 14 internists in practice. An open phase
of 6 weeks during which treatment consisted only of a diuretic
(mefruside, 25 mg/day), was followed by four treatment periods
of 4 weeks each in randomized sequence consisting of placebo,
debrisoquine (20 mg/day), methyldopa (1000 mg/day), or pro-
pranolol (160 mg/day). Mefruside was continued at the same
dose. At the end of the open phase, the blood pressure of 48
patients with essential hypertension remained elevated at 168/
Ill 20/14 mm Hg (mean SD). A significant fall in blood pres-
sure was achieved not only at the end of active treatments but
also after administration of placebo with the blood pressure
reaching 160/103 20/11 mm Hg. Compared with placebo, blood
pressure was significantly lower during the active medication pe-
riods. However, the comparative fall for systolic blood pressure
ranged only from 6 (debrisoquine) to 12 (methyldopa) mm Hg
and for diastolic from 4 (debrisoquine) to 5 mm Hg (methyldopa,
propranolol), with no significant difference appearing between
active drugs. Propranolol was slightly better tolerated than the
others. After the study period, antihypertensive therapy at the
choice of the internist was continued in 36 patients. In these pa-
tients, with free choice of medication the drop in blood pressure
averaged 10/9 mm Hg. Conclusions. In the hands of practicing
internists, the antihypertensive efficacy of debrisoquine, methyl-
dopa, and propranolol is essentially equal. However, at the
doses used they were only slightly more effective than placebo.
Not surprisingly, internists in practice are able to obtain better
antihypertensive results when allowed free choice of medication.
Chloride reabsorption in various conditions of hypokalemia in
man. G. Williams, L. Favre, G. Lucot, H. Favre, andM. B. Val-
lotton. Divisions d'Endocrinologie et de Néphrologie, Hôpital
Cantonal, Genève, Switzerland. Because a defect in chloride
transport has been proposed as a specific cause of Bartter's syn-
drome, the relationship between fractional distal delivery of
chloride (FDD1) and fractional reabsorption of chloride (FDR1)
was studied in 8 patients with potassium depletion, by using
clearance techniques under maximal water diuresis. Two pa-
tients had all the characteristics of Bartter's syndrome; despite
chronic treatment with indomethacin, hypokalemia was still
present (plasma K, 2.2 and 2.3 mmoles/liter). Among the 6 other
K-depleted patients (plasma K, 1.7 to 3.4 mmoles/liter), there
were 2 cases of psychogenic vomiting, 2 laxative abusers, 1 case
of anorexia nervosa, and 1 experimental subject given a low-K
diet and cation exchange resin. For the 6 latter patients, FDR1
was positively correlated with inulin clearance (r = 0.63, P <
0.05), and inversely correlated with FDD1 (r = —0.94, P <
0.001), but completely unrelated to plasma K. In the 2 patients
with Bartter's syndrome, FDR1 was slightly lower than ex-
pected from the latter regression (0.63 and 0.72, c.f. predicted
0.85 and 0.87). However, these 2 values were similar to those
observed in 2 other hypokalemic patients having decreased in-
ulin clearance and increased FDD1 without Bartter's syndrome.
As the 2 cases of Bartter's syndrome had normal inulin clear-
ance, the effect of low GFR on FDR could not be evaluated in
this syndrome. After withdrawing indomethacin in one of the 2
cases, FDRCI remained unchanged, suggesting that prostaglan-
dins do not affect chloride reabsorption. Thus, a reduced FDR1
may well be a feature of Bartter's syndrome, but may also be
found in various conditions of potassium depletion associated
with renal failure, and consequently it cannot be used as a specif-
ic diagnostic criterium.
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Ticrynafen (tienilic acid), a uricosuric diuretic drug. G. G.
Geyskes, B. B. A. Laemers, J. J. M. van Bussel, P. Boer, and F.
J. Dorhout Mees. Department of Nephrology and Hypertension,
University Hospital, Utrecht, The Netherlands. In 24 patients
with essential hypertension (as defined by the World Health Or-
ganization as stages I and II) whose blood pressure remained>
130/90 during chronic atenolol treatment, the effects of adding
250 mg of ticrynafen (TCN) or 50 mg of chlortalidone (CHT)
were investigated in a double-blind crossover study. Serum uric
acid decreased during TCN and increased during CHT; CHT al-
so increased serum cholesterol concentration. As compared to
CHT, TCN caused less blood pressure reduction and less vol-
ume depletion (as measured by body weight and plasma renin
activity).
When CHT was replaced by TCN, the average urinary creati-
nine excretion of all patients was significantly lower on the first
day of TCN following CHT as compared to the preceding day on
CHT, but not on the first day TCN after placebo. One patient
complained of loin tenderness and showed diminished urine pro-
duction on the first day TCN directly following CHT in the pre-
ceding period. Blood studies revealed a renal insufficiency that
improved gradually after discontinuation of TCN. To study the
effect of replacing chronic CHT by TCN in more detail, we per-
formed a study in five hospitalized patients, also with essential
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Day 0 Day 1 Day 2 Day 5 Day 14 Day 28
Patient 1
chiortalidone, mg 50
ticrynafen, mg 250 250 250 250 250
serum urea,mmo/es/liter 12.6 21.3 27.1 17.0 17.1
serum creatinine, pmoles/liter 170 355 410 180 185
diuresis, mi/day 2275 1370 2865
Patient 2
chiortalidone, mg 50
ticrynafen, mg 250 250
serumurea,mmoles/liter 7.4 17.5 23.2 41.0 16.4 6.3
serum creatinine, p.moles/liter 70 300 515 690 140 100
diuresis,mi/day 1175 72 80 1570 1840
Patient 3
chiortalidone, mg 100
ticrynafen, mg 500 500
serum urea,mmoles/liter 7.7 16.2 20.8 32.0 12.9 8.1
serum creatinine, uno1es/liter 90 355 530 800 200 115
diuresis, m//day 1060 280 807 1660 1960
hypertension. One patient developed a moderate renal in-
sufficiency on the first day of TCN that was reversible during
continued TCN treatment. Two other patients developed frank
oliguria on the first day of TCN; TCN was discontinued; the in-
crease of blood urea and creatinine was maximal on day 5 and
returned to normal pretreatment values in the following 3 weeks
(see Table 1). The high frequency of this renal complication in
the first day on TCN, following chronic CHT therapy, but not
after placebo, points to a possible interaction of the two drugs.
The exact nature of the renal insufficiency is not known. Uric
acid nephropathy seems unlikely because the uric acid excretion
in the first urine samples during TCN was not high, and no uric
acid crystal were seen. Renal insufficiency during TCN after pre-
ceding CHT therapy is a frequently occurring serious complica-
tion. It warrants caution during more general use of this other-
wise valuable drug.
Effects of oral converting enzyme inhibitor, Captopril, on renin
and blood pressure in renovascular hypertension and anephric
subjects.J. H. B. de Bruyn, A. J. Man in 't Veld, G. J. Wenting,
F. H. M. Derkx, 1. M. Schicht, and M. A. D. H. Schalekamp.
Department of Internal Medicine I, University Hospital Dijkzigt,
Rotterdam and Department of Nephrology, University Hospital
Leiden, Leiden, The Netherlands. The renin-angiotensin (RA)
system and kallikrein-kinin (KK) system share the enzyme, kin-
inase II converting enzyme. Until now the blood pressure drop
after converting enzyme inhibition with Captopril (C) has been
claimed to be caused by falling levels of circulating angiotensin
II. In anephric subjects, 2 hours after fluid withdrawal during
heamodialysis, causes a significant drop in blood pressure in con-
trast to placebo. This fall in blood pressure is maximal after 24
hours and even more pronounced on standing, orthostatic hypo-
tension developing in all patients. After fluid repletion, C had no
effect on blood pressure in these patients. Renin is very low in
these patients, so the blood pressure drop can not be accounted
for by changes in circulating angiotensin II alone. Another con-
nection between the RA system and the KK system is seen in the
process of activation of inactive plasma renin (IR) in vitro. After
acid-treatment, IR is converted at pH 7.5 into active renin (AR).
This activation at pH 7.5 can be blocked by adding Trasylol®.
So, this activation of IR is caused by an endogenous serine pro-
tease. Exogenous serine proteases such as trypsin are equally
effective in activating IR at pH 7.5. In prekallikrein (Fletcher
factor) -deficient plasma as well as in factor-XII (Hagemen fac-
tor) -deficient plasma, acid activation of IR does not occur, in
contrast with activation of IR by trypsin. In plasma, activation of
prekallikrein is caused by factor XII. Adding active kallikrein to
factor-XII-deficient plasma caused activation of IR to values not
different from trypsin treatment. Adding active factor XII to pre-
kallikrein-deficient plasma had no effect. So plasma kallikrein is
the major endogenous activator of IR in vivo. After nephrectomy
IR falls to values not different from those seen in low-renin es-
sential hypertension (LHT). After C, IR rises in LHT; in aneph-
nc subjects IR does not change. So IR has an important extra-
renal source. The presence of the kidney, however, is essential
for changes in IR after stimulation. In patients with unilateral
renal artery stenosis, levels of JR in renal artery and renal vein
on the affected side are not different. After stimulation by C, JR
in the renal vein fell to levels far below those in the renal artery.
In contrast, AR in the renal vein rose markedly. These opposite
changes in AR and IR suggest activation of IR in vivo. Whether
kallikrein plays a role in this activation process in vivo or not is
not clear. In vitro experiments during acid activation of IR and
prekallikrein show that almost all IR is activated, as prekallikrein
levels have fallen by less than 10%. So the possible changes of
plasma prekalhikrein and kallikrein during activation of IR in vivo
will be small and hardly demonstrable.
Renal vascular tachyphylaxis to angiotensin II in the dog: Speci-
ficity and the role of prostaglandins and bradykinin. P. W. de
Leeuw, L. G. Meggs, N. K. Hollenberg, and W. H. Birkenhager.
Department of Medicine and Radiology, Peter Bent Brigham
Hospital and Harvard Medical School, Boston, Massachusetts,
USA and Department of Medicine, Zuiderziekenhuis, Rotter-
dam, The Netherlands. A hypothesis concerning angiotensin's
role in sustained renal vasoconstriction must account for the rap-
id development of tachyphylaxis to angiotensin II (All). Data
from the literature suggest that prostaglandins (PG's) may be in-
volved in this process. Because these could act either by recep-
tor modulation or by nonspecific vasodilation, we studied the ef-
fect of All and norepinephnne (NE) on the renal vasculature
(electromagnetic flow meter) in the anesthetized dog. In a first
series of experiments (6 dogs), tachyphylaxis to All infused into
the renal artery was demonstrated within 10 mm. The response
to NE was well-maintained at that time, but disappeared in some
dogs with prolonged infusion. In another group of 7 dogs, we
found that PGE1, in a dose that increased renal blood flow by
30% did not modify the response to bolus injections of All or
NE. Equivalent doses of PGEZ (5 dogs), PGF2,, (6 dogs), and
PGI2 (7 dogs) showed similar results. Infusion of bradykinin
(BK), however, completely abolished and even reversed the re-
sponse to All and NE (10 dogs). We conclude that specific de-
sensitization to All (tachyphylaxis) may be followed by a non-
specific offsetting vasodilating mechanism. If PG's are involved
in All tachyphylaxis, and as yet not identified PG must be the
mediator. Endogenous BK may serve as a modulator of renal
vascular tone and reactivity.
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Anti-T-cell specificity in nephritogenic antibodies. W. W. Bak-
ker, W. M. Bagchus, J. T. W. M. Vos, K. Kooistra, and Ph. J.
Hoedemaeker. Department of Pathology, State University of
Groningen, Groningen, The Netherlands. Injection of rats with
rabbit antibodies against the brushborder (BB) of proximal tu-
bules of the rat kidney results in immediate immune complex
formation along the epithelial side of the glomerular basement
membrane (GBM). Previous experiments suggested that these
anti-BB antibodies also possess an in vitro cytotoxic activity
against rat thymocytes. We have compared the specificities of
anti-BB antibodies with antirat thymocytes (anti-THY) anti-
bodies using direct migration inhibition assays, as well as a cyto-
toxicity assay on thymocytes using guinea pig serum as com-
plement source. Immunofluorescent studies with these sera were
performed on normal frozen kidney sections, and absorption
studies were carried out using the BB antigen, thymocyte, and
brain extracts; the latter extracts were used as thymocyte mem-
brane (THY) antigens. (Thymocyte membrane antigens are re-
ferred to as Thy, which is not identical to the purified Thy-i anti-
gen in the rat, although this material contains probably much
Thy-i antigen, which is present in considerable amounts in rat
brain and thymus cells.)
The results indicate that (I) anti-BB as well as anti-THY anti-
bodies are able to stain brushborders in frozen kidney sections.
This staining can be abolished by absorption of the antisera with
BB antigen but not with THY antigens. (2) Both anti-BB and
anti-THY antibodies can induce a dose-related migration inhibi-
tion of thymocytes. These activities of either anti-BB or anti-
THY antibodies can be inactivated after absorption to their re-
spective antigens. Absorption with THY antigen removes, how-
ever, the activity from anti-BB sera partially, as does absorption
with BB-antigen of anti-THY antisera. (3) Both anti-BB anti-
bodies and anti-THY antibodies are cytotoxic for rat thymocytes
in vitro. The cytotoxicity of anti-BB antibody can be absorbed
with both BB and THY antigens. Cytotoxicity of anti-THY anti-
sera can be absorbed, however, only with THY antigens. Ab-
sorption with BB antigens only reduces partially this cytotoxic
activity. From these results, we concluded that anti-BB anti-
bodies contain at least two specificities: one directed against BB
antigens and one directed against THY antigens. One the other
hand, anti-THY antibodies contain mainly antibodies directed
against THY antigens and to a lesser extent to BB antigens. The
findings of this study indicate some relation exists between BB
and THY antigens, which might be important in the pathogenesis
of experimental autologous and heterologous immune complex
glomerulopathy, especially in view of recent concepts on in situ
formation of immune complexes in this type of experimental dis-
ease.
Triple drug treatment of autologous immune complex glomeru-
lonephritis. G. J. Fleuren and P. J. Hoedemaeker. Deparment of
Pathology, Groningen, The Netherlands. Autologous immune
complex glomerulonephritis (AIC), an established experimental
model of membranous glomerulopathy in man, which is induced
in rats through immunization with renal tubular antigens (Fx1A),
has been used to investigate the effect of various drugs on its
course. Because immunosuppressive or anti-inflammatory drugs
were reported to have little or no effect on AIC, a combination of
cyclophosphamide, azathioprine, and prednisolone (triple drug)
was used in this study. Because we previously reported that AIC
probably results from binding of free-circulating anti-Fx 1A anti-
body to antigens present in the glomerular basement membrane
(GBM), special attention was paid to the effect of triple drug
treatment on the anti-FxiA serum titers and the relation between
these titers, deposition of immune aggregates along the GBM,
and the occurrence of proteinuria. It was found that triple-drug
treatment consisting of 9 mg/kg cyclophosphamide, 9 mg/kg
azathiopnne, and 3.6 mg/kg prednisolone, given three times a
week simultaneously with the immunization procedure, could
completely prevent formation of anti-Fx IA antibody and deposi-
tion of immune aggregates in the glomeruli, as well as develop-
ment of proteinuria. It triple-drug treatment was injected daily
during 6 weeks from week 9 onwards, a moment when immune
deposits were present along the GBM but proteinuria had not yet
developed, a decrease in serum titers of anti-FxlA antibody, di-
minished deposition of immune aggregates along the GBM, and a
significant decrease of proteinuria were found. In later stages of
the disease, when proteinuria was developed, no beneficial effect
of triple-drug treatment could be demonstrated. Proteinuria per-
sisted in these rats, although complement was not present any-
more along the GBM, which indicates that proteinuria in later
stages of AIC is independent of complement binding. We con-
clude that the beneficial effect of triple-drug treatment in early
stages of AIC is caused by a decrease in the level of free-circulat-
ing anti-FxIA antibody. The lack of benifit in later stages of AIC
probably can be explained by the fact that proteinuria in these
stages results from structural damage of the GBM caused by pre-
viously deposited immune aggregates instead of from deposition
of newly formed immune aggregates.
Antibody nature of C3 nephritic factor. M. R. Daha and L. A.
van Es. University Hospital, Leiden, The Netherlands. The ca-
pacity of serum from patients with membranoproliferative gb-
merulonephntis (MPGN) or partial lipodistrophy (PLD) to inter-
act with normal human serum to inactivate C3 by the alternative
pathway of complement activation, as assessed by loss of the B
antigen of C3 was ascribed to the presence of C3 nephritic factor
(C3NeF). The action of nephritic serum was magnesium-depen-
dent and requires at least B, D, and C3. C3NeF, defined by the
capacity of nephritic serum and its fractions to initiate loss of the
BD, antigen of C3 in normal serum was functionally purified
from the serum of five patients with MPGN and from serum of
three patients with PLD, and shown to function by stabilization
of the membrane-bound and fluid phase amplification convert-
ase, C3bBb. Stabilization of C3bBb by C3NeF occurs by binding
of C3NeF to the convertase. Further purification of C3NeF from
nonspecific IgU was obtained by binding of C3NeF to fluid phase
C3bBb, and subsequent ultracentrifugation; C3bBb (C3NeF)
sediments at lOS, well separated from IgG. Highly purified
C3NeF was obtained by dissociation of C3bBbC3NeF and sub-
sequent chromatography on QAE-A50 columns. '251-C3NeF was
shown to bind for at least 92% to cell-bound C3bBb, indicating
conservation of functional activity. '251-C3NeF from the eight pa-
tients has a mol wt of 150,000 daltons, and is composed of two
heavy and two light chains of 53,000 and 23,500 daltons, respec-
tively. Because these data suggested that C3NeF was an IgU, its
antigenic reactivity with sepharose-bound antisera was investi-
gated. it was found that '251-C3NeF reacted with antisera against
K, A, Yi, Y2, and y. These results indicate that C3NeF is an im-
munoglobulin of the IgG class, capable of binding to C3bBb. To
determine whether the Fab portion of the antibody was involved
in stabilization of C3bBb, we subjected '251-C3NeF to pepsin and
papain digestion, respectively. The Fab and Fab fragments thus
generated were tested for their capacity to bind to C3bBb and to
stabilize the convertase. Fab and Fab were four and nine times
less active than was intact C3NeF to stabilize C3bBb, respec-
tively. There was a direct relationship between the number of
F(ab) and Fab bound to C3bBb and the rate of stabilization.
These results indicate that C3NeF is an antibody of the IgG
class, with specificity for the C3bBb convertase.
One year's experience with 26 high-risk patients on continuous
ambulatory peritoneal dialysis. N. Lameire, M. De Paepe, E.
Matthijs, S. Ringoir. Renal Division of the Department of Inter-
nal Medicine, University Hospital, De Pintelaan, Gent, Belgium.
Our 1-year experience with 26 patients on continuous ambulatory
peritoneal dialysis (CAPD) is presented. All patients were con-
sidered high-risk patients for hemodialysis because of old age,
impossible vascular access, diabetes, or recent cardiovascular
accidents. We used four exchanges of 2 liters each per 24 hours.
Serum creatinine and blood urea at 9 months stabilized at 80%
and 70% of the initial level, respectively. The use of a zero-potas-
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sium dialysate resulted in hypokalemia in 5 patients requiring po-
tassium supplements. Slight metabolic acidosis (mean plasma bi-
carbonate, 22 mEg/liter) was present at 9 months. We noted nor-
mal serum calcium and slightly elevated serum phosphorus, a
dramatic increase in hematocrit with 6.5 volume per volume in 9
months, and a 20% fall in serum PTH at 6 months. The mean
daily loss of protein in the dialysate was between 7 and 11 g, but
the peritoneal creatinine clearance remained unchanged over a 9-
month interval. The incidence of peritonitis was one episode per
6.3 patient-months. All episodes of peritonitis were cured with
i.p. antibiotics. Sometimes dramatic deterioration of a pre-
existing hyperlipemia was noted in 50% of the patients. Two non-
diabetic patients with plasma triglycerides over 1000 mgldl were
treated with small daily doses of crystalline insuline and respond-
ed with a 50% fall in their plasma lipids. We conclude that CAPD
is an excellent alternative way of treatment of chronic renal fail-
ure in high-risk patients. We suggest that a dialysate containing 2
mEq/liter potassium and a lactate concentration of 40 mEq/liter
should be available.
Successful 6-day kidney-preservation by a combination of a hy-
pothermic continuous- and a 3-hour normothermic ex vivo per-
fusion: An experimental study. B. G. Rijkmans, J. v. d. WUk, A.
J. M. Donker, M. J. H. Slooff, and G. Kootstra. Department of
Surgery, State University Hospital, Groningen, The Nether-
lands. The purpose of the study was to investigate the possibility
of extending the preservation time of kidneys, allowing more
time for advanced immunologic donor/recipient matching. In six
mongrel dogs (weight, 21 to 24kg) the right kidney was removed,
flushed with a Collins-solution (40 C), and then perfused in a
Gambro-preservation machine for 6 days. A 5% Kabi® albumin
solution was used as perfusate. After 6 days, autotransplantation
in the neck of the animal was performed, followed by con-
tralateral nephrectomy. This series served as control for another
group of six dogs, in which the period of 6 days of hypothermic
machine perfusion was halfway interrupted by 3 hours normo-
thermic ex vivo perfusion. With the animals under general anes-
thesia, the femoral vessels of the same animal were canulated
and connected via silastic tubing with the artery and vein of the
kidney that was placed in an organ chamber. In the control
group, only one out of six dogs survived, versus six out of six in
the cx vivo perfused group. The only survivor of the control
group had a significantly higher serum creatinin concentration
(maximum level, 1080 smoles/liter on day 5) after implantation,
than did the ex vivo perfused group (average maximum level, 576
smoles/liter on day 2). These results indicate a beneficial effect
of normothermic ex vivo perfusion halfway the preservation-pe-
riod. In previous experiments, not presented here, we found that
in our model the optimal cx vivo perfusion time was between 2
and 4 hours. During the cx vivo perfusion and 1 hour after im-
plantation, the effective renal plasma flow (ERPF), the GFR, and
the filtration fraction (FF) were calculated from clearances of
'311-hippuran and '25-iothalamate. The seven dogs that survived
had variable values for GFR (range, 0.027 to 12 mI/mm.) and
ERPF (range, 0.16 to 47.48 mllmin) at 1 hour after implantation.
(In this study, the value of the ERPF should not be considered as
an approximation of the true renal plasma flow but rather as a
measure of the proximal tubular function.) In all seven cases,
however, a low FF (range, 0.07 to 0.26) was found, whereas a
high FF (range, 0.52 to 1) was measured in the dogs that died.
From these findings, we conclude that shortly after implantation,
signs of active tubular secretion are more important than are the
absolute values of GFR and ERPF. During the normothermic cx
vivo perfusion, halfway the preservation period, a marked in-
crease of the ERPF and the GFR were found, total renal blood
flow being constant. The increase in ERPF was greater than was
the rise in GFR, resulting in a slight decrease in FF. An increase
in urine concentration was observed during the cx vivo per-
fusion. These data indicate an improving extraction and water
resorbtion of recovering proximal tubules during the normother-
mic cx vivo perfusion. The results of this study will be the basis
for a new experimental model, in which the animal in the cx vivo
perfusion is replaced by an artificial heart-lung circuit. So, time
could be provided to extend the preservation period, and, on the
other hand, this system might provide the opportunity to monitor
and resuscitate a damaged kidney before transplantation.
In vivo action of interferon under circumstances of immuno-
suppression. W. Weimar, L. W. Stitz, A. de Reus, and H.
Schellekens. Department of Internal Medicine I and Virology,
Erasmus University Rotterdam, and Primate Center TNO, Virol-
ogy Section, Rijswijk, The Netherlands. Viral infections occur
frequently in renal transplant recipients. One possible way to
control these infections is the use of interferon. Interferons are
species-specific glycoproteins with antiviral properties in vitro
and in vivo. The effective prophylactic dosage of human inter-
feron is unknown, however. Attempts to prevent viral disease in
renal transplant recipients with interferon proved to be not fully
successful. In a primate model, we tried to find the optimal inter-
feron dose, and we studied the efficacy of interferon under cir-
cumstances of immunosuppression. The prophylactic antiviral
activity of systemically administrated interferon was tested in 48
rhesus monkeys against vaccinia virus injected into the skin. In-
terferon was administred from day — 1 (before vaccination) to
day +7 after vaccination. Results. All control animals developed
typical vaccinia pustulae. Human leukocyte interferon (HLI) in a
dose of 5 x 10 U/kg, given iv. and i.m., protected the monkeys
completely. No lesions developed after discontinuation of thera-
py. Lower dosage HLI diminished lesion size. Human fibroblast
interferon (HFI) in a dosage of 5 > l0 U/kg resulted in com-
parable efficacy as 1.25 X l0 U/kg HLI. Under immuno-
suppression of prednisone (6 mg/kg) and azathioprine (3 mg/kg),
HLI was still active and decreased lesion size. HLI was fully
active in the monkeys who received ALS (horse antihuman, 5 x
120 mg/kg): no lesions developed in these animals, but in their
controls typical vaccinia pustulae were seen. Conclusions. Sys-
temically administered HLI and HF! can protect rhesus mon-
keys against vaccinia virus. Only 5 x l0 U/kg HLI was fully
effective. HLI is also active under circumstances of immuno-
suppression.
Protection against rejection by impaired blood flow in a renal
allograft. K. J. M. Assmann, R. A. P. Koene, R. G. W. Tiggeler,
J. G. M. Rosier, and H. P. C. van Roermund. Department of
Pathology and Department of Medicine, Division of Nephrolo-
gy, St. Radboudziekenhuis, University of Nmegen, The Nether-
lands. Antibodies, directed against transplantation antigens, play
an important role in the pathogenesis of chronic vascular rejec-
tion. The occurrence of tissue destruction is determined by the
concentration of these antibodies, the density of the correspond-
ing antigens on the allograft, and the presence of secondary me-
diators, like an effective complement system. Nonimmunologic
factors may also be important. An observation in a patient with a
renal transplant showed that the degree of perfusion is one of the
factors that can extensively modify humoral rejection. A 44-
year-old man received a kidney allograft for treatment of termi-
nal renal insufficiency that was caused by an allergic vasculitis.
The cadaver kidney had two arteries that were anastomosed sep-
arately to the iliac artery of the recipient. A renal biopsy taken 1
year later, showed a chronic vascular rejection. On arteri-
ography we found a 90% stenosis in the artery that supplied the
lower pole of the kidney. One half year later, renal failure had
developed, and the graft was removed. After the trans-
plantectomy, cytotoxic antibodies were demonstrable in the
serum. The glomeruli in the ischemic lower pole segment did not
demonstrate any sign of vascular rejection, and this was in strik-
ing contrast to the upper kidney segment. Immunoglobulin de-
posits and complement were found abundantly in the upper seg-
ment, but not in the lower part. The arteries in either part of the
allograft had a similar degree of intimal fibrosis, but deposits of
immunoglobulins and complement were not present in the vessel
walls. These findings demonstrate that a reduction of the renal
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perfusion in a segment of the kidney not only protects this part tion, as could be derived from the changes in the nonischemic
against a vascular rejection but also can prevent the deposition of part of the kidney and from the demonstration of circulating anti-
antibodies. These antibodies were actually present in the circula- bodies after removal of the graft.
